Clinical Trial Update: Poractant Alfa (Curosurf®)) -- Effect in Adult Patients Diagnosed With 2019 Novel Coronavirus (SARS-COV-19; (Covid-19)) Acute Respiratory Distress Syndrome (ARDS) [Phase 2]

View source ↗

Summary

Phase 2 trial updating on poractant alfa (Curosurf) for adults with ARDS due to COVID-19; the study is terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome

Drugs mentioned

• Curosurf (poractant alfa)

Snippet

Sponsor: Chiesi Farmaceutici S.p.A. | Conditions: Acute Respiratory Distress Syndrome | Phase 2 | Status: TERMINATED | Results posted: 2023-06-23